WuXi Further Pharmaceutical Co., Ltd

A new "exercise pill" Irisin is a boon for dieters

Irisin is a protein secreted by muscles that promotes the conversion of white fat cells into brown fat cells and increases metabolic rate. Its mechanism of action is formed through shearing and modification and acts on white fat cells (Figure 1). The discovery of irisin provides a new idea for the treatment of obesity ( Figure 2).

On April 16, 2024, the team of Professor Rui Yongjun, Dean of Wuxi Ninth School Affiliated to Soochow University published online article that entitled "Irisin alleviates obesity-induced bone loss by inhibiting interleukin 6 expression via TLR4/MyD88/NF-κB axis in adipocytes in the international authoritative Journal of Advanced Research (Figure 3) . The article demenstrate that Irisin has the following biological activities:

 Figure 3 

1. Irisin’s deficiency exacerbates HFD-induced obesity and fat content;

2. In imaging, irisin’s deficiency aggravated HFD-induced bone loss;

3. Irisin’s deficiency, in histology, aggravated HFD-induced bone loss;

4. Irisin’s deficiency exacerbates HFD-induced bone formation reduction;

5. Irisin inhibits the adipogenesis of bone marrow mesenchymal stem cells;

6. Irisin can reduce the inhibitory effect of adipocytes on bone formation of bone marrow mesenchymal stem cells;

7.Irisin reduces the secretion of inflammatory factors by adipocytes;

8.Irisin inhibits IL-6 secretion from adipocytes through the TLR4/MyD88/NF-κB pathway;

9.Irisin deficiency increases the expression of TLR4 and IL-6 in the bone marrow cavity of HFD mice;

Conclusions:

1. Adipocytes in obesity inhibit osteogenic differentiation of bone marrow mesenchymal stem cells.

2. Irisin can reduce bone loss caused by obesity by inhibiting the secretion of IL-6 by adipocytes.

3. Inhibition of IL6 secretion by irisin in adipocytes is mediated by inhibition of TLR4/MyD88/NF-κB pathway.

4. The therapeutic potential of irisin in preventing obesity-induced bone loss was revealed